This bill amends 21 U.S.C. §505(q) to restrict the use of citizen petitions as a litigation tactic to slow or block approval of generic drugs, 505(b)(2) products, and biosimilars filed under section 351(k) of the PHS Act. It forces would‑be challengers to bring issues to the FDA first and gives the agency clearer tools to identify submissions that are primarily intended to delay approvals.
The change matters for branded manufacturers, generic and biosimilar applicants, public‑interest petitioners, and courts. By compressing the timeline and expanding the criteria the FDA may use to classify a petition as dilatory, the bill aims to reduce last‑minute hold‑ups that postpone market entry and patient access—but it also creates new procedural traps and factual questions that will shape future agency guidance and litigation strategy.
At a Glance
What It Does
The bill requires anyone seeking judicial relief that would set aside or block an application under 505(b)(2), 505(j), or 351(k) to file a citizen petition first, and to include in that petition all information and arguments they would later raise in court. It adds a 180‑day filing deadline measured from when the petitioner knew the underlying information and authorizes the FDA to use a list of specific factors to decide whether a petition was intended primarily to delay an approval.
Who It Affects
Directly affects generic and biosimilar applicants awaiting FDA action, branded companies that use petitions defensively, entities that file citizen petitions (including competitors, trade groups, and public‑interest organizations), and federal courts that hear challenges to FDA approvals.
Why It Matters
The bill changes the tactical dance around citizen petitions: it shifts the timing calculus, raises the stakes for petition content and timing, and replaces ambiguous exhaustion arguments with statutory dismissal rules—potentially speeding market entry for generics but also sparking disputes over when petitioners ‘knew’ the facts and what constitutes final agency action.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The amendments rewrite how citizen petitions interact with litigation over approvals of generic, 505(b)(2), and biosimilar applications. Under the new text, a petitioner who hopes to sue to halt or overturn FDA action must first file a petition that lays out every argument and piece of information the petitioner might later use in court.
That requirement converts what previously might have been a narrow or strategic filing into a full administrative submission.
The bill imposes a firm procedural deadline: any petition or supplemental petition must be submitted within 180 days after the filer knew the facts that form the basis of the request. The statute does not leave the ‘‘knew’’ question wholly undefined; instead it directs the agency to consider timing and reasonableness in assessing when knowledge occurred.
If petitioners miss that window, courts are required to dismiss their lawsuits—with the statute distinguishing between dismissals for failure to exhaust administrative remedies and dismissals with prejudice for failure to file timely petitions.To police abusive filings, the bill supplies the FDA with a non‑exclusive list of factors it may weigh when deciding whether a petition was filed primarily to delay an approval. Those factors include whether the petition was filed close to a known approval date, whether it lacks supporting data, whether it repeats issues already substantively addressed by the agency, and whether it asks the FDA to impose more onerous standards on other applicants.
The FDA can issue guidance to amplify or clarify these considerations.Practically, the law also makes targeted technical edits—adding a reference to a related regulation (10.31), changing language from “application and” to “application or,” and swapping some internal subparagraphs—so that the statutory framework and FDA procedures align. The combined effect is to make last‑minute petitions a riskier and more administratively exposed strategy, while giving applicants and the agency clearer statutory ammunition to move approvals forward.
The Five Things You Need to Know
The bill requires petitioners to file a citizen petition before initiating any civil action that would seek to set aside, delay, rescind, withdraw, or prevent submission/review/approval of an application under 505(b)(2), 505(j), or 351(k).
A petition or any supplement must be submitted within 180 days after the petitioner knew the information that forms the basis of the petition or supplement.
The FDA may consider specific dilatory factors—including serial petitions, timing close to a projected approval date, lack of supporting scientific data, and requests for stricter testing or labeling standards than those FDA applies to other applicants—when deciding whether a petition was submitted primarily to delay.
If a petitioner fails to file the required petition, a court must dismiss the subsequent suit without prejudice for failure to exhaust administrative remedies; if the petitioner misses the 180‑day window, the court must dismiss with prejudice for failure to timely file.
The statute authorizes FDA to issue or update guidance describing the factors it will use and inserts a regulatory cross‑reference (10.31) to align the agency’s procedural regulations with these changes.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds regulatory cross‑reference and refines language
This subpart inserts a reference to 21 C.F.R. 10.31 alongside 10.30 and makes minor wording adjustments (for example, changing “application and” to “application or” and replacing “submission of this petition” with “submission of this document”). Those edits are technical but matter for how FDA treats different types of filings and which regulations the agency invokes when processing petitions and communications from parties.
Enumerates factors FDA may use to find a petition dilatory
The bill replaces the older, shorter test with a detailed, non‑exclusive list of factors the FDA can weigh when determining whether a petition was submitted primarily to delay. The list includes timing relative to when petitioners knew facts, serial or duplicative filings, proximity to an anticipated approval date, absence of supporting scientific data, repetition of issues already addressed by FDA, requests to impose standards more onerous than FDA’s established standards, and the petitioner’s prior history of petitions deemed dilatory. The provision also permits FDA to publish guidance describing additional relevant factors.
Pre‑suit petition requirement and 180‑day filing deadline
This new subsection (A)/(B) requires would‑be plaintiffs to submit a citizen petition before filing suit and to include in that petition all information and arguments they intend to raise in litigation. It creates a 180‑day clock measured from when the petitioner knew the information underpinning the petition; supplements must also comply with that timing. By converting pre‑litigation issues into a statutorily required administrative record, the bill narrows opportunities for surprise litigation and sets up predictable procedural consequences for late filings.
Statutory dismissal rules for courts
The bill replaces ad hoc judicial exhaustion analysis with explicit dismissal outcomes tied to petition compliance: courts must dismiss without prejudice for failures to exhaust (i.e., suing before filing a petition), dismiss with prejudice when petition timeliness (the 180‑day rule) is violated, and dismiss without prejudice when the petitioner has filed timely but the FDA has not yet reached final agency action. This calibrated set of consequences changes litigation strategy and raises stakes for procedural compliance.
Narrows statutory exceptions and cleans up structure
The bill removes one of the prior enumerated exceptions and retools the paragraph structure, consolidating clauses and adjusting headings. The net effect is to tighten the statutory gatekeeping around petitions that could delay approvals and reduce the number of carve‑outs available to petitioners seeking to avoid the new procedural hurdles.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Generic and biosimilar applicants: They gain reduced exposure to last‑minute petitions and a clearer statutory path to seek dismissal of dilatory lawsuits, which can shorten the pathway to market entry and reduce litigation costs.
- FDA (agency staff and review divisions): The agency receives statutory support for policing abusive petitions and may be able to manage its docket more predictably, allowing review resources to focus on substantive safety and efficacy issues rather than repetitive procedural filings.
- Courts and judges handling FDA litigation: Clear, statutory dismissal standards lower the burden of preliminary judicial fact‑finding about exhaustion and timeliness, reducing piecemeal litigation and remands tied to administrative exhaustion disputes.
- Patients and payers awaiting lower‑cost generics and biosimilars: Faster resolution of procedural delays can accelerate competition and earlier availability of lower‑cost alternatives.
Who Bears the Cost
- Brand manufacturers and competitors that use citizen petitions defensively: They face tighter timing rules and a higher risk that tactical petitions will be deemed dilatory or lead to lawsuits being dismissed with prejudice.
- Public‑interest organizations, academics, and whistleblowers: Groups that bring safety‑focused petitions may be chilled by the 180‑day ‘knew’ standard or fear sanctions/dismissal if they cannot document when they acquired specific information.
- Small petitioners and trade associations with limited legal resources: The requirement to include all litigation arguments in the administrative petition and to meet a 180‑day deadline increases legal drafting and fact‑gathering burdens, potentially raising compliance costs.
- FDA resource lines managing petitions: Although the bill aims to reduce abusive filings, the agency may need additional staff and procedural resources to implement new guidance, evaluate dilatory intent under the enumerated factors, and defend its determinations in court.
Key Issues
The Core Tension
The central dilemma is balancing protection against strategic, last‑minute petitions that impede competition and delay patient access, against preserving a meaningful, timely administrative avenue for legitimate safety or efficacy concerns; tightening procedural barriers reduces abusive delay but risks silencing or precluding meritorious challenges that arise or are discovered close to an approval date.
The bill's practical effect depends on how the FDA defines and applies the ‘‘knew’’ standard and the enumerated dilatory factors. Determinations about when a petitioner reasonably should have known relevant facts are inherently factual and will generate litigation over record evidence, which could shift battles from whether a petition was filed to when and how petitioners acquired information.
That dispute is costly to litigate and may create uneven outcomes depending on the resources available to parties.
The 180‑day deadline and the statutory distinction between dismissal with prejudice and dismissal without prejudice create sharp consequences for late or procedurally defective filings. A dismissal with prejudice for an untimely petition is a strong remedy that could permanently foreclose judicial review of certain claims, raising procedural fairness concerns when claimants have legitimate, newly discovered safety data.
The provision permitting FDA guidance helps the agency provide clarity, but guidance itself can be challenged and will take time to produce, leaving an interim period of uncertainty. Finally, because the bill treats petition content as a proxy for litigation intent, soliciting more complete administrative records may advantage well‑funded actors while disadvantaging smaller public‑interest filers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.